BeOne Medicines Ltd. – Sponsored ADR $ONC Stock Position Cut by Capital International Inc. CA

Capital International Inc. CA decreased its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 5.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 325,844 shares of the company’s stock after selling 19,715 shares during the period. BeOne Medicines makes up 0.9% of Capital International Inc. CA’s portfolio, making the stock its 28th biggest position. Capital International Inc. CA owned about 0.30% of BeOne Medicines worth $111,015,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Anchor Investment Management LLC acquired a new position in shares of BeOne Medicines during the second quarter valued at approximately $26,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines during the 2nd quarter valued at $35,000. EverSource Wealth Advisors LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter valued at $68,000. Steward Partners Investment Advisory LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter worth $169,000. Finally, Montag A & Associates Inc. bought a new stake in shares of BeOne Medicines in the 2nd quarter worth $182,000. 48.55% of the stock is currently owned by institutional investors.

Insider Activity at BeOne Medicines

In other news, CEO John Oyler sold 24,369 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total transaction of $7,380,639.03. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Chan Henry Lee sold 1,660 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total transaction of $580,203.20. The disclosure for this sale is available in the SEC filing. Insiders sold 102,656 shares of company stock valued at $31,567,496 over the last three months. Insiders own 6.62% of the company’s stock.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $302.29 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $196.45 and a fifty-two week high of $385.22. The stock’s 50-day moving average is $335.51 and its two-hundred day moving average is $330.31. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.41 and a quick ratio of 3.08. The firm has a market cap of $33.15 billion, a P/E ratio of 119.96 and a beta of 0.53.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Sanford C. Bernstein raised BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a report on Monday, January 12th. Morgan Stanley restated an “overweight” rating and set a $405.00 price objective on shares of BeOne Medicines in a research report on Thursday, January 8th. Royal Bank Of Canada boosted their target price on shares of BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reissued a “buy” rating and set a $420.00 target price on shares of BeOne Medicines in a research note on Monday, November 17th. Finally, Wall Street Zen lowered shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $401.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.